VERU VERU INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 863894 · Fiscal year ends 09/30
Financial factors as of 2024-09-30 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.6%
TTM net income YoY59.4%
TTM EPS YoY—
Revenue 3-yr CAGR-34.9%
Net income 3-yr CAGR—
Margins
Gross margin34.7%
Operating margin-214.2%
Net margin-223.9%
FCF margin-129.3%
EBITDA margin-213.0%
Returns
ROE-145.4%
ROA-68.5%
ROIC (approx.)-327.4%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets46.5%
Debt / equity0.00x
Current ratio2.97x
Interest coverage-59.54x
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-29.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | $0 | $0 | — | $6.66M |
| Cost of revenue | — | — | — | — | — | — | — | $3.97M |
| Gross profit | — | — | — | — | — | — | — | $2.69M |
| R&D expense | $4.35M | $3.15M | $1.34M | $2.92M | $3.02M | $3.93M | $5.72M | $3.29M |
| SG&A expense | $3.36M | $4.07M | $4.08M | $4.54M | $5.01M | $5.16M | $5.23M | $6.25M |
| Operating income | -$7.71M | -$7.22M | -$5.42M | $1.17M | -$7.55M | -$8.12M | -$10.25M | -$9.34M |
| Interest expense | — | — | — | — | — | — | — | $169,867 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.99M | -$2.74M | -$5.33M | $1.45M | -$7.33M | -$7.90M | -$8.95M | -$8.53M |
| EBITDA | -$7.69M | -$7.19M | -$5.40M | $1.20M | -$7.52M | -$8.09M | -$10.18M | -$9.28M |
| EPS (basic) | -0.30 | -0.12 | -0.26 | — | -0.50 | -0.54 | -0.61 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $23.88M | $27.60M | $32.99M | $15.79M | $15.01M | $20.02M | $26.61M | $24.92M |
| Receivables | — | — | — | — | — | — | — | $3.96M |
| Inventory | — | — | — | — | — | — | — | $4.14M |
| Current assets | $27.23M | $33.36M | $36.81M | $18.92M | $16.19M | $21.38M | $28.38M | $35.22M |
| PP&E, net | $280,227 | $308,421 | $336,615 | $364,808 | $393,381 | $422,712 | $452,043 | $481,372 |
| Goodwill | $6.88M | $6.88M | $6.88M | $6.88M | $6.88M | $6.88M | $6.88M | $6.88M |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $37.03M | $43.08M | $47.57M | $29.84M | $27.33M | $32.67M | $39.83M | $60.42M |
| Current liabilities | $6.16M | $5.39M | $7.13M | $7.79M | $6.68M | $5.62M | $6.35M | $11.87M |
| Total liabilities | $8.65M | $8.30M | $10.44M | $11.50M | $11.99M | $11.62M | $13.20M | $28.10M |
| Shareholders' equity | $28.38M | $34.79M | $37.12M | $18.33M | $15.34M | $21.05M | $26.63M | $32.32M |
| Shares outstanding | 17.05M | 16.05M | 16.05M | 14.65M | 14.65M | 146.58M | 146.38M | 14.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.47M | -$8.91M | -$6.17M | -$5.49M | -$5.48M | -$7.74M | -$11.33M | -$4.37M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $1,083 | $63,036 |
| Free cash flow | -$5.47M | -$8.91M | -$6.17M | -$5.49M | -$5.48M | -$7.74M | -$11.33M | -$4.43M |
| Investing cash flow | $1.80M | $3.52M | $0 | $6.28M | $474,064 | $1.15M | $17.25M | $131,500 |
| Financing cash flow | -$51,914 | $0 | $23.37M | $0 | $0 | $0 | -$4.22M | $0 |
| Depreciation & amortization | $28,000 | $28,000 | $28,193 | $28,573 | $29,000 | $29,000 | $64,870 | $65,144 |
| Stock-based compensation | $577,969 | $402,712 | $757,605 | $1.53M | $1.67M | $2.22M | $2.67M | $3.23M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.